1. Expert Scientific Group (ESG) On Phase One Clinical Trials. Final Report. 2006:1‒107.
2. Parexel. Clinical trial protocol: A phase-1, single-centre, double-blind, randomised, placebo-controlled, single escalating dose study, to assess the safety, pharmacokinetics, pharmacodynamics and immunogenicity of TGN1412 administered intravenously to healthy volunteers. 2000:1‒58.
3. TGN1412: From Discovery to Disaster;Attarwala;J Young Pharm,2010
4. The TeGenero Incident and the Duff Report Conclusions: A Series of Unfortunate Events or an Avoidable Event;CJ;Toxicol Pathol,2009
5. Loss of Siglec expression on T lymphocytes during human evolution;Nguyen;PNAS,2006